| |
Summer Institute on Longitudinal Research &
National Drug Abuse Treatment Clinical Trials
Network (CTN) Dissemination Conference
August 9-11, 2010
Clinical Trials Network
Thomas Freese, Ph.D.
UCLA Integrated Substance Abuse Programs
DAY TWO – Tuesday, August 10, 2010
Clinical Workshop
Track 3: Evidence-based Approaches for Substance Abuse Treatment Providers
Breakout A
PRESENTATION/HANDOUTS:
“Promoting Awareness of Motivational Interventions (PAMI)”
SELECTED REFERENCES:
Carroll, K.M., Sinha, R., Nich, C., Babuscio, T. & Rounsaville, B. J. (2002). Contingency management to enhance naltrexone treatment of opioid dependence: A randomized clinical trial of reinforcement magnitude. Experimental and Clinical Psychopharmacology, 10(1), 54-63.
Griffith, J.D., Rowan-Szal, G.A., Roark, R.R., & Simpson, D.D. (2000). Contingency management in outpatient methadone treatment: A meta-analysis. Drug and Alcohol Dependence, 58(1), 55-66.
Heil, S.H., Tidey, J.W., Holmes, H.W., Badger, G.J., Higgins, S.T. (2003). A contingent payment model of smoking cessation: Effects on abstinence and withdrawal. Nicotine & Tobacco Research, 5, 205-213.
Petry, N.M., Kolodner, K.B., Li, R., Peirce, J.M., Roll, J.M., Stitzer, M.L. & Hamilton, J.A. (2006). Prize-based contingency management does not increase gambling. Drug and Alcohol Dependence, 83, 269-273.
DAY THREE – Wednesday, August 11, 2010
Clinical Workshop
Track 2: Evidence-based Approaches for Substance Abuse Treatment Providers
Breakout A
PRESENTATION/HANDOUTS:
“Training for Multidisciplinary Treatment Providers: Understanding Buprenorphine”
SELECTED REFERENCES:
Martino, S., Brigham. G.S., Higgins, C., Gallon, S., Freese, T.E., Albright, L.M., Hulsey, E.G., Krom, L., Storti, S.A., Perl, H., Nugent, C.D., Pintello, D. & Condon, T.P. (2010). Partnerships and pathways of dissemination: The National Institute on Drug Abuse – Substance Abuse and Mental Health Services Administration Blending Initiative in the Clinical Trials Network. Journal of Substance Abuse Treatment, 38(Suppl 1), S31-43.
Ling, W., Amass, L., Shoptaw, S., Annon, J.J., Hillhouse, M., Babcock, D., Brigham, G., Harrer, J., Reid, M., Muir, J., Buchan, B., Orr, D., Woody, G., Krejci, J., Ziedonis, D. & the Buprenorphine Study Protocol Group. (2005). A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction, 100(8), 1090-1100.
Amass, L., Ling, W., Freese, T.E., Reiber, C., Annon, J.J., Cohen, A.J., McCarty, D., Reid, M.S., Brown, L.S., Clark, C., Ziedonis, D.M., Krejci, J., Stine, S., Winhusen, T., Brigham, G., Babcock, D., Muir, J.A., Buchan, B.J. & Horton, T. (2004). Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA Clinical Trials Network field experience. American Journal of the Addictions, 13(Suppl 1), S42-S66.
Sullivan, L.E., Chawarski, M., O’Connor, P.G., Schottenfeld, R.S. & Fiellin, D.A. (2005). The practice of office-based buprenorphine treatment of opioid dependence: Is it associated with new patients entering into treatment? Drug and Alcohol Dependence, 79, 113-116.
Top of Page
|
|
